Form 4: Mirum Pharmaceuticals Director Laurent Fischer Receives Significant Equity Compensation

Mirum Pharmaceuticals, Inc. Director Laurent Fischer was granted 6,268 stock options and 3,977 restricted stock units on May 29, 2025, as part of his compensation package.

Summary

• Laurent Fischer, a Director at Mirum Pharmaceuticals, Inc. (MIRM), was granted equity awards on May 29, 2025.
• The awards include 6,268 stock options with an exercise price of $44.00 per share.
• Additionally, 3,977 Restricted Stock Units (RSUs) were granted, each representing a contingent right to receive one share of the Issuer's common stock.
• Both the stock options and RSUs are scheduled to vest on the first anniversary of the grant date, or in any case, will be fully vested by the date of the Issuer's 2026 annual stockholder meeting.
• The stock options have an expiration date of May 28, 2035.

Sentiment

Score: 6

Explanation: The filing reports a routine equity grant to a director, which is a positive for aligning interests and is a standard corporate practice, but it does not indicate significant new operational or financial news that would dramatically alter the company's outlook.

Positives

• The grant of equity awards to Director Laurent Fischer aligns his financial interests with those of the company's shareholders, incentivizing long-term performance and value creation.
• Equity compensation is a standard and effective practice for attracting and retaining experienced board members, ensuring their commitment to the company's success.

Negatives

• No negative information or adverse events are presented in this routine insider transaction filing.

Risks

• This Form 4 filing, which details an insider equity grant, does not disclose specific operational, financial, or strategic risks to Mirum Pharmaceuticals, Inc.

Future Outlook

The granted stock options and restricted stock units are subject to future vesting schedules, with full vesting by the first anniversary of the grant date or the company's 2026 annual stockholder meeting, whichever comes first. This indicates a future alignment of the director's compensation with the company's long-term performance.

Industry Context

The granting of stock options and restricted stock units to directors is a common and widely accepted form of executive and board compensation across various industries, particularly prevalent in the biotechnology and pharmaceutical sectors. This practice aims to align the interests of leadership with shareholder value creation and long-term company performance.

Comparison to Industry Standards

• The compensation structure, involving both stock options and restricted stock units with a vesting schedule, is consistent with typical equity compensation practices for directors in publicly traded pharmaceutical companies.
• While specific comparable companies are not named in the filing, this type of grant is a standard mechanism used by companies like Gilead Sciences, Amgen, or Biogen to incentivize and retain board members, though the specific grant size and exercise price would vary based on company size, performance, and individual roles.

Stakeholder Impact

• Shareholders: The equity grants align the director's interests with shareholder value creation, potentially leading to better long-term decision-making and increased focus on company performance.
• Employees: No direct impact on general employees is indicated by this specific filing, as it pertains to director compensation.

Next Steps

• Vesting of the granted stock options and restricted stock units will occur according to the specified schedule, either on the first anniversary of the grant date or by the Issuer's 2026 annual stockholder meeting.

Key Dates

Keywords

Mirum Pharmaceuticals, MIRM, Laurent Fischer, SEC Form 4, Insider Transaction, Stock Option, Restricted Stock Units, Equity Compensation, Director Compensation, Vesting Schedule